Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | MARS1 | P56192 | 3/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrosine SCHEMBL9051836 | 0.92 | SLC7A5 (0.56) | SLC7A5 | |
| SCHEMBL464778 | 0.87 | ALPI (0.50) | SLC7A5 | |
| SCHEMBL4453960 | 0.85 | SLC7A5 (0.67) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL27680265 | 0.85 | SLC7A5 (0.67) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| Tyrosine SCHEMBL180585 | 0.83 | SLC7A5 (0.71) | SLC7A5TAAR1SLC6A2 | |
| Tyrosine SCHEMBL180587 | 0.83 | SLC7A5 (0.71) | SLC7A5TAAR1SLC6A2 | |
| Tyrosine SCHEMBL28430992 | 0.83 | SLC7A5 (0.71) | SLC7A5TAAR1SLC6A2 | |
| SCHEMBL9521810 | 0.81 | SLC7A5 (0.54) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL2490445 | 0.81 | SLC7A5 (0.57) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL4279625 | 0.81 | SLC7A5 (0.61) | SLC7A5TAAR1SLC6A2ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019078697-A2 | ANTI-CD3 ANTIBODY AND PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT COMPRISING SAME | 주식회사 녹십자 | 2019-04-25 | — | — | WO | disclosed |
| US-20150111816-A1 | METHODS AND TREATMENT WITH GLP-1 RECEPTOR AGONISTS | PHASEBIO PHARMACEUTICALS, INC. (US) | 2015-04-23 | — | — | US | disclosed |
| US-20140364362-A1 | THERAPEUTIC AGENTS COMPRISING INSULIN AMINO ACID SEQUENCES | PHASEBIO PHARMACEUTICALS INC (US) | 2014-12-11 | — | — | US | disclosed |
| EP-1750521-A1 | METHOD AND SYSTEM FOR SOLUBILIZING PROTEIN | The Texas A&M University System (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005117602-A1 | METHOD AND SYSTEM FOR SOLUBILIZING PROTEIN | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2005-12-15 | — | — | WO | disclosed |
| US-5062935-A | METHOD OF VAPORIZING A SAMPLE SUBSTANCE | BRUKER-FRANZEN ANALYTIK GMBH (DE) | 1991-11-05 | — | — | US | disclosed |